Legend Biotech Financials - Benzinga

Legend Biotech Corp

LEGNNASDAQ

Trade with Public

Trade with Public

$21.82

0.562.63%

At close: Aug 21, 5:00 PM EST

$21.82

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Legend Biotech Financials

Legend Biotech (LEGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the

Benzinga Newsdesk

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.

Avi Kapoor

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the

Benzinga Newsdesk

Earnings Scheduled For March 10, 2026

Benzinga Insights

Legend Biotech Q4 Earnings Summary & Key Takeaways

Benzinga Insights